MONDAY, Nov. 16, 2020 (HealthDay News) — BioNTech and Pfizer’s experimental coronavirus vaccine could cut transmission of the virus in half, leading to a “dramatic” curb of its spread, according to a company executive.
“I’m very confident that transmission between people will be reduced by such a highly effective vaccine — maybe not 90% but maybe 50%,” said Ugur Sahin, chief executive of Germany’s BioNTech, the Associated Press reported.
Last week, the companies claimed the vaccine was 90% effective in protecting people from the new coronavirus.
“If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year,” Sahin said. “Our goal is to deliver more than 300 million of vaccine doses until April next year, which could allow us to already start to make an impact.”
Researchers are gathering more information on safety and manufacturing quality of the vaccine, the AP reported.
Copyright © 2020 HealthDay. All rights reserved.